FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052294822> ?p ?o ?g. }

• W2052294822 endingPage "643" @default.
• W2052294822 startingPage "636" @default.
• W2052294822 abstract "Background Crizotinib produces high response rates and prolonged PFS in ALK+ NSCLC. Retrospective analyses suggest enhanced sensitivity to pemetrexed in crizotinib naive ALK+ NSCLC. Cross-resistance between crizotinib and pemetrexed has not been previously investigated. Patients and Methods Patients with stage IV ALK+ NSCLC treated with PEM-CRIZ, or CRIZ-PEM were identified. Overall PFS and PFS excluding central nervous system events (eCNS) were compared. Results Objective response rates in evaluable patients were 66% (PEM-CRIZ) and 75% (CRIZ-PEM) for pemetrexed and 84% (CRIZ-PEM) and 66% (PEM-CRIZ) for crizotinib. For PEM-CRIZ (n = 29), median PFS and eCNS PFS were both 6 months with pemetrexed, and 10 and 14.5 months, respectively, with crizotinib. For CRIZ-PEM (n = 9), median PFS and eCNS PFS were 4.5 and 3 months, respectively, with pemetrexed, and 8.5 and 7.5 months, respectively, with crizotinib. There was a statistically significant increase in the risk of an overall PFS event with pemetrexed when administered after crizotinib (P = .0277; hazard ratio [HR], 2.5898; 95% confidence interval [CI], 1.1100-6.0424), but differences in the risk of an eCNS PFS event were not significant (P = 0.4913; HR, 1.3521; 95% CI, 0.5727-3.1920). Neither overall nor eCNS PFS for patients while taking crizotinib was associated with a sequence effect relative to pemetrexed. Conclusion Crizotinib and pemetrexed are active drugs in ALK+ NSCLC. PFS benefit appeared higher with crizotinib than with pemetrexed. PFS benefit from pemetrexed was less after crizotinib compared with before crizotinib, however, this difference was only statistically significant for overall and not eCNS PFS. Pemetrexed exposure did not seem to affect crizotinib outcomes." @default.
• W2052294822 created "2016-06-24" @default.
• W2052294822 creator A5008692987 @default.
• W2052294822 creator A5025836672 @default.
• W2052294822 creator A5034705456 @default.
• W2052294822 creator A5045959942 @default.
• W2052294822 creator A5054803331 @default.
• W2052294822 creator A5060160370 @default.
• W2052294822 creator A5062914325 @default.
• W2052294822 creator A5072767282 @default.
• W2052294822 creator A5082517668 @default.
• W2052294822 date "2013-11-01" @default.
• W2052294822 modified "2023-10-07" @default.
• W2052294822 title "Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer" @default.
• W2052294822 cites W1985329793 @default.
• W2052294822 cites W2019539885 @default.
• W2052294822 cites W2019607817 @default.
• W2052294822 cites W2022008113 @default.
• W2052294822 cites W2030227571 @default.
• W2052294822 cites W2040317578 @default.
• W2052294822 cites W2050249255 @default.
• W2052294822 cites W2055402151 @default.
• W2052294822 cites W2075875937 @default.
• W2052294822 cites W2081095165 @default.
• W2052294822 cites W2084618926 @default.
• W2052294822 cites W2096156234 @default.
• W2052294822 cites W2104830962 @default.
• W2052294822 cites W2105067160 @default.
• W2052294822 cites W2113327188 @default.
• W2052294822 cites W2134667653 @default.
• W2052294822 cites W2134787029 @default.
• W2052294822 cites W2135329354 @default.
• W2052294822 cites W2139110945 @default.
• W2052294822 cites W2139939379 @default.
• W2052294822 cites W2147038864 @default.
• W2052294822 cites W2158638287 @default.
• W2052294822 cites W2161984323 @default.
• W2052294822 doi "https://doi.org/10.1016/j.cllc.2013.06.005" @default.
• W2052294822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4126227" @default.
• W2052294822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23931899" @default.
• W2052294822 hasPublicationYear "2013" @default.
• W2052294822 type Work @default.
• W2052294822 sameAs 2052294822 @default.
• W2052294822 citedByCount "22" @default.
• W2052294822 countsByYear W20522948222014 @default.
• W2052294822 countsByYear W20522948222015 @default.
• W2052294822 countsByYear W20522948222016 @default.
• W2052294822 countsByYear W20522948222017 @default.
• W2052294822 countsByYear W20522948222018 @default.
• W2052294822 countsByYear W20522948222019 @default.
• W2052294822 countsByYear W20522948222020 @default.
• W2052294822 countsByYear W20522948222022 @default.
• W2052294822 crossrefType "journal-article" @default.
• W2052294822 hasAuthorship W2052294822A5008692987 @default.
• W2052294822 hasAuthorship W2052294822A5025836672 @default.
• W2052294822 hasAuthorship W2052294822A5034705456 @default.
• W2052294822 hasAuthorship W2052294822A5045959942 @default.
• W2052294822 hasAuthorship W2052294822A5054803331 @default.
• W2052294822 hasAuthorship W2052294822A5060160370 @default.
• W2052294822 hasAuthorship W2052294822A5062914325 @default.
• W2052294822 hasAuthorship W2052294822A5072767282 @default.
• W2052294822 hasAuthorship W2052294822A5082517668 @default.
• W2052294822 hasBestOaLocation W20522948222 @default.
• W2052294822 hasConcept C117643217 @default.
• W2052294822 hasConcept C126322002 @default.
• W2052294822 hasConcept C143998085 @default.
• W2052294822 hasConcept C2776232967 @default.
• W2052294822 hasConcept C2776256026 @default.
• W2052294822 hasConcept C2776694085 @default.
• W2052294822 hasConcept C2777240266 @default.
• W2052294822 hasConcept C2778239845 @default.
• W2052294822 hasConcept C2778347629 @default.
• W2052294822 hasConcept C2779422266 @default.
• W2052294822 hasConcept C71924100 @default.
• W2052294822 hasConceptScore W2052294822C117643217 @default.
• W2052294822 hasConceptScore W2052294822C126322002 @default.
• W2052294822 hasConceptScore W2052294822C143998085 @default.
• W2052294822 hasConceptScore W2052294822C2776232967 @default.
• W2052294822 hasConceptScore W2052294822C2776256026 @default.
• W2052294822 hasConceptScore W2052294822C2776694085 @default.
• W2052294822 hasConceptScore W2052294822C2777240266 @default.
• W2052294822 hasConceptScore W2052294822C2778239845 @default.
• W2052294822 hasConceptScore W2052294822C2778347629 @default.
• W2052294822 hasConceptScore W2052294822C2779422266 @default.
• W2052294822 hasConceptScore W2052294822C71924100 @default.
• W2052294822 hasIssue "6" @default.
• W2052294822 hasLocation W20522948221 @default.
• W2052294822 hasLocation W20522948222 @default.
• W2052294822 hasLocation W20522948223 @default.
• W2052294822 hasLocation W20522948224 @default.
• W2052294822 hasOpenAccess W2052294822 @default.
• W2052294822 hasPrimaryLocation W20522948221 @default.
• W2052294822 hasRelatedWork W1974903221 @default.
• W2052294822 hasRelatedWork W2057269827 @default.
• W2052294822 hasRelatedWork W2162074187 @default.
• W2052294822 hasRelatedWork W2319183095 @default.
• W2052294822 hasRelatedWork W2439017782 @default.
• W2052294822 hasRelatedWork W2533300620 @default.

• next